Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised Phase II Trial to Evaluate Progression-Free Survival in Integrating Local Ablative Therapy With First-Line Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer

NCT05862051 is registered in ClinicalTrials.gov with Australasian Gastro-Intestinal Trials Group as lead sponsor.

NCT NCT05862051
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05862051 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised Phase II Trial to Evaluate Progression-Free Survival in Integrating Local Ablative Therapy With First-Line Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer
Lead sponsor
Australasian Gastro-Intestinal Trials Group
Phase
Not applicable
Overall status
Active, not recruiting
Start date
December 14, 2021
Completion date
December 31, 2027
Enrollment
6 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, oligometastatic disease